Clinical

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 hospitalizations over 5 years.

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities with accurate information.

The antiretroviral (ART) regimen Biktarvy showed higher 1-year ART persistence and lower switch rates among people with HIV.

Symptoms of dry eye improved when patients in Canada used reproxalap compared with a placebo dose.

Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.

Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.

Posters presented at AMCP Nexus 2025 found especially low oral HIV PrEP uptake among transgender individuals and those facing insurance challenges.

Panelists discuss how the treatment landscape has evolved from limited options to include hypomethylating agents and venetoclax combinations, with emerging oral formulations promising greater accessibility while requiring careful consideration of patient selection and toxicity management.

Panelists discuss how prescription digital therapeutics differ from traditional pharmaceuticals by following FDA medical device approval pathways focused on clinical performance and safety rather than chemistry and manufacturing while offering potential economic value by extending behavioral health capacity to underserved populations, especially in rural areas with limited mental health professionals.

Panelists discuss how combination trials like VIALE-A and VIALE-C have demonstrated venetoclax’s survival benefits when added to hypomethylating agents, opening doors for numerous combination studies while emphasizing the need for randomized trials to prove clinical benefit in different disease contexts.

Panelists discuss how schizophrenia imposes significant economic costs across direct medical expenses, nonmedical expenses, and indirect costs, with negative symptoms particularly amplifying the burden by reducing patient engagement, work capacity, and treatment adherence while increasing relapse risk and total cost of care.

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, said Kristina Crothers, MD.

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing cardiovascular and renal benefits through unclear but likely multiple mechanisms, with the elegant advantage of single-dose efficacy regardless of diabetes status or heart failure type.

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA approval across the ejection fraction spectrum and recent generic availability improving cost-effectiveness, though ACE inhibitors and ARBs remain viable second-line options when ARNI is not accessible.

Multidrug combinations may counteract the role of cytokines in drug resistance, a new review article explains.

Tumor-first multigene testing boosts diagnostic accuracy, minimizes duplication, and aligns with professional society recommendations for integrated sequencing.

Artificial intelligence models may advance clinical trial design and enrollment to improve trial success and patient outcomes.

Liver Awareness Month raises awareness of liver disease causes, risks, symptoms, and prevention, highlighting individual actions and policy efforts.

The FDA approved revumenib for relapsed/refractory (R/R) acute myeloid leukemia, offering a new targeted therapy option for patients with NPM1 mutations.

Increases in global temperatures may exacerbate cardiovascular mortality risk in older patients with heart failure.

This timeline highlights 5 key dates in September when the FDA approved treatments for cancers, dermatologic conditions, and rare diseases.